FSSAI Orders Removal of ‘ORS’ from Food and Beverage Labels

New Delhi– The Food Safety and Standards Authority of India (FSSAI) has directed all food and beverage manufacturers to immediately remove the term “ORS” (Oral Rehydration Solution) from product labels, citing misleading claims about health benefits.

The order aims to prevent consumer confusion, as only medically certified ORS products can use the term. Non-compliance will attract fines up to ₹10 lakh. Manufacturers have 30 days to update packaging. FSSAI emphasized stricter enforcement to protect public health.

Background: Public Interest Litigation

The regulatory intervention follows a nearly decade-long campaign by Hyderabad-based paediatrician Dr. Sivaranjani Santosh against sugar-rich beverages falsely marketed as ORS. In 2022, she filed a Public Interest Litigation (PIL) in the Telangana High Court challenging beverages that claimed to be ORS but failed to meet WHO-recommended electrolyte and glucose standards.

Her petition highlighted the potential health risks, especially to children and diabetic patients, and her complaints reached the Ministry of Health and Family Welfare, prompting regulatory scrutiny.

Court and Regulatory Actions

The Telangana High Court directed FSSAI and the Drug Controller General of India to respond, recognising the public health implications of misleading ORS claims.

In April 2022, FSSAI issued its first restriction, but in July the regulator temporarily allowed companies holding valid trademarks to continue production until the Controller General of Patents, Designs and Trademarks issued a final decision.

Health Risks from Mislabelled Beverages

WHO-approved ORS has a total osmolarity of 245 mOsm/L, with precise quantities of sodium, potassium, chloride, and dextrose. In contrast, many marketed products contained up to 120 grams of sugar per litre, with minimal electrolytes, posing serious health risks.

Related Posts

Doctor, nurse removed after 2 maternal deaths in Jodhpur

Jodhpur: A new mother died Friday after being referred from the Govt Sub-District Hospital in Bhopalgarh to Ummed Hospital in Jodhpur district headquarters following complications during childbirth, prompting the medical…

Rajasthan Bans Common Anaesthesia Injection Batch Used In Caesarean Deliveries And Surgeries: What Patients Need To Know

Rajasthan Drug Controller Ajay Phatak said that the Bupivacaine Hydrochloride in Dextrose, manufactured by Themis Medicare Limited, Batch No. BKP02601 has been restricted for sale and use. The Rajasthan Drug…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Doctor, nurse removed after 2 maternal deaths in Jodhpur

Doctor, nurse removed after 2 maternal deaths in Jodhpur

Aster Quality Care all set to make Advanced Healthcare Ubiquitous in India

Aster Quality Care all set to make Advanced Healthcare Ubiquitous in India

Rajasthan Bans Common Anaesthesia Injection Batch Used In Caesarean Deliveries And Surgeries: What Patients Need To Know

Rajasthan Bans Common Anaesthesia Injection Batch Used In Caesarean Deliveries And Surgeries: What Patients Need To Know

Raj orders statewide inspection of blood centres for compliance with safety norms

Raj orders statewide inspection of blood centres for compliance with safety norms

mRNA Vaccines Proven Safe And Highly Effective Against Severe Infectious Diseases, Finds Lancet Review

mRNA Vaccines Proven Safe And Highly Effective Against Severe Infectious Diseases, Finds Lancet Review

Telangana bets big on drug discovery hub

Telangana bets big on drug discovery hub